阿达木单抗用于治疗白塞病中威胁视力的葡萄膜炎。
Adalimumab for sight-threatening uveitis in Behçet's disease.
作者信息
Mushtaq B, Saeed T, Situnayake R D, Murray P I
机构信息
Birmingham and Midland Eye Centre, Birmingham, UK.
出版信息
Eye (Lond). 2007 Jun;21(6):824-5. doi: 10.1038/sj.eye.6702352. Epub 2006 Apr 7.
PMID:16601736
Abstract
AIMS
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
METHODS
Case note review. Main outcome measure was recurrence of uveitis.
RESULTS
All patients remained free of recurrence with stable visual acuities.
CONCLUSIONS
Adalimumab appears to maintain disease remission in Behçet's disease.
摘要
目的
描述三名使用英夫利昔单抗维持治疗的白塞病患者转换为阿达木单抗治疗后的临床结局。
方法
病历回顾。主要结局指标为葡萄膜炎复发情况。
结果
所有患者均未复发，视力稳定。
结论
阿达木单抗似乎能维持白塞病的病情缓解。
Zotero 插件